ArticleBiomaterials research2025
Thermo-responsive Bioink for Personalized 3D Printed Scaffolds with Antioxidant and Fibroblast Delivery to Accelerate Diabetic Wound Healing.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MXene Bioinks for 3D Bioprinting: Design and Translation.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Bioprinting in Tissue Repair and Its ENT Applications.Polymers · 2026Review
- A Thermoresponsive, Electrically Conductive Bioink Optimized for Electroactive Tissue Engineering and Bioelectronics.ACS applied bio materials · 2026Article
- Engineering next-generation organoids: A review on bioprinting strategies, bioink innovations, and frontier applications.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three-dimensional (3D) bioprinting is a promising field in tissue engineering, and the mechanical properties and biocompatibility of bioinks are essential factors. This study introduces a biocompatible, thermo-responsive poly(organophosphazene)-based bioink with excellent mechanical properties that provides effective drug release. First, we synthesized the Tyr-PPZ polymer, which contained an isoleucine ethyl ester, amino-methoxy poly(ethylene glycol), and tyramine. The Tyr-PPZ polymer was dissolved in phosphate-buffered saline to prepare TP bioink. The presence of hydrophobic components facilitated the homogeneous diffusion of caffeic acid into the bioink and conferred antioxidant properties. The PC bioink, prepared by incorporating caffeic acid into TP bioink, not only exhibited stable antioxidant properties but also showed excellent extrudability and printability due to its shear-thinning and recovery properties, which enabled the fabrication of various 3D scaffolds. Printed 3D scaffolds maintained high mechanical properties at body temperature (37 °C), which ensured scaffold stability for 30 d without additional cross-linking. In addition, to enhance diabetic wound healing through antioxidant properties and fibroblast delivery, PCC bioink was formulated by loading fibroblasts into PC bioink. Three-dimensional scaffolds fabricated using PCC bioink exhibited high cell viability for 7 d and promoted tissue regeneration in diabetic mice. In addition, PCC bioink provided antioxidant effects and accelerated wound closure, thick granulation tissue formation, and angiogenesis. This technology is promising as a next-generation bioink platform for diabetic wound treatment through a high-resolution 3D bioprinting scaffold that effectively delivers antioxidants and fibroblasts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.